WhitcombJMParkinNTChappeyCet al.
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis2003;
188: 992–1000.
2.
MarcelinA-G.Resistance to nucleoside reverse transcriptase inhibitors. In: GerettiAM (ed.) Antiretroviral Resistance in Clinical Practice.
London:
Mediscript, 2011.
3.
PhamQDWilsonDPLawMGet al.
Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS2014;
28: 2751–2762.
4.
BrooksJINiznickHOfnerMet al.
Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions. BMC Infect Dis2013;
13: 509.
5.
CapettiAFSterrantinoGCossuMVet al.
Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort. Antivir Ther2017;
22: 257–262.
6.
WalmsleySLAntelaAClumeckNet al.
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med2013;
369: 1807–1818.
7.
RaffiFRachlisAStellbrinkH-Jet al.
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet2013;
381: 735–743.
8.
ClotetBFeinbergJvan LunzenJet al.
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet2014;
383: 2222–2231.
9.
YazdanpanahYFagardCDescampsDet al.
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis2009;
49: 1441–1449.
